The Safety Committee of the European Medicines Agency (PRAC) has recommended the withdrawal of medicines containing levamisole from the European Union market.[1] Levamisole was indicated for the treatment of nephrotic syndrome, specifically to prevent relapse in patients whose disease has been controlled with corticosteroids.[1] The Committee for Medicinal Products for Human Use (CHMP) had reservations about the way the main clinical trial was conducted and the lack of information about the drug's effects, its distribution in the body and the risks of interactions with other drugs.[1] The CHMP concluded that the benefits of Elmisol in the proposed indication do not outweigh its risks.[1] ACE Pharmaceuticals BV officially withdrew its application for marketing authorization on 29 May 2017 after the CHMP evaluated the original dossier.[1]